We are live on
!
Find out more
Jacobs Levy Equity Management Portfolio holdings
AUM
$23.8B
1-Year Est. Return
25.4%
This Fund
S&P 500
This Quarter
Est. Return
+3.27%
1 Year Est. Return
+25.4%
3 Year Est. Return
+87.35%
5 Year Est. Return
+125.75%
10 Year Est. Return
+515.94%
AUM
$7.23B
AUM Growth
+$298M
(+4.3%)
Cap. Flow
+$149M
Cap. Flow
% of AUM
2.07%
Top 10 Holdings %
Top 10 Hldgs %
15.39%
Holding
1,100
New
151
Increased
415
Reduced
333
Closed
164
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$40.6M |
| 2 |
Autodesk
ADSK
|
+$38.8M |
| 3 |
Intuit
INTU
|
+$37.1M |
| 4 |
Ecolab
ECL
|
+$35.6M |
| 5 |
Coca-Cola
KO
|
+$35.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$51.9M |
| 2 |
EOG Resources
EOG
|
+$33.8M |
| 3 |
DATA
Tableau Software, Inc.
DATA
|
+$32M |
| 4 |
Microsoft
MSFT
|
+$29.8M |
| 5 |
Ford
F
|
+$29.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.67% |
| 2 | Financials | 17.68% |
| 3 | Consumer Discretionary | 13.74% |
| 4 | Industrials | 11.53% |
| 5 | Healthcare | 11.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
LITS
801
Lite Strategy Inc
LITS
$33.6M
| $339K | ﹤0.01% |
6,776
+5,919
| +691% | +$347K |
|
802
Accenture
ACN
$89.9B
| $335K | ﹤0.01% |
1,813
-590
| -25% | -$106K |
|
|
CNST
803
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $329K | ﹤0.01% |
+26,801
| New | +$298K |
|
804
Spyre Therapeutics
SYRE
$8.87B
| $328K | ﹤0.01% |
+1,914
| New | +$331K |
|
|
ISEE
805
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $323K | ﹤0.01% |
248,261
-69,686
| -22% | -$95.6K |
|
806
NextEra Energy
NEE
$187B
| $315K | ﹤0.01% |
+6,160
| New | +$303K |
|
807
Home Bancorp
HBCP
$552M
| $312K | ﹤0.01% |
8,116
+1,860
| +30% | +$67.3K |
|
|
AGTC
808
DELISTED
Applied Genetic Technologies Corporation
AGTC
| $309K | ﹤0.01% |
81,624
+18,265
| +29% | +$74.9K |
|
809
US Bancorp
USB
$99.6B
| $308K | ﹤0.01% |
5,870
+280
| +5% | +$14.4K |
|
|
SRC
810
DELISTED
SPIRIT REALTY CAPITAL, INC.
SRC
| $307K | ﹤0.01% |
+7,190
| New | +$303K |
|
|
AAT
811
American Assets Trust
AAT
$1.49B
| $306K | ﹤0.01% |
+6,500
| New | +$299K |
|
|
JNCE
812
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $306K | ﹤0.01% |
61,766
+46,266
| +298% | +$246K |
|
|
NSTG
813
DELISTED
NanoString Technologies, Inc.
NSTG
| $304K | ﹤0.01% |
10,000
| – | – |
|
|
BHR
814
Braemar Hotels & Resorts
BHR
$153M
| $298K | ﹤0.01% |
30,399
+4,767
| +19% | +$56.6K |
|
815
Syndax Pharmaceuticals
SNDX
$1.84B
| $298K | ﹤0.01% |
32,032
+15,832
| +98% | +$115K |
|
816
H.B. Fuller
FUL
$3B
| $297K | ﹤0.01% |
6,410
+1,520
| +31% | +$70.1K |
|
817
Myers Industries
MYE
$1.18B
| $297K | ﹤0.01% |
+15,400
| New | +$277K |
|
|
GIFI
818
DELISTED
Gulf Island Fabrication
GIFI
| $296K | ﹤0.01% |
41,713
+5,500
| +15% | +$45.4K |
|
819
Enpro
NPO
$7.05B
| $292K | ﹤0.01% |
4,572
| – | – |
|
820
Zebra Technologies
ZBRA
$12.4B
| $289K | ﹤0.01% |
1,380
| – | – |
|
821
Astec Industries
ASTE
$1.3B
| $285K | ﹤0.01% |
8,749
-3,000
| -26% | -$101K |
|
822
Scholar Rock
SRRK
$5.71B
| $282K | ﹤0.01% |
+17,770
| New | +$329K |
|
823
Freshpet
FRPT
$2.83B
| $281K | ﹤0.01% |
+6,170
| New | +$279K |
|
824
Qualys
QLYS
$4.84B
| $281K | ﹤0.01% |
+3,230
| New | +$279K |
|
|
FTSV
825
DELISTED
Forty Seven, Inc. Common Stock
FTSV
| $279K | ﹤0.01% |
+26,358
| New | +$387K |
|
Similar funds
OAG
CHP
SAM
JG
Jacobs Levy Equity Management's Q2 2019 Portfolio in Review
As of Q2 2019, Jacobs Levy Equity Management held 1,100 positions worth $7.23B, up 4.3% from $6.93B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Jacobs Levy Equity Management's Q2 2019 filing shows 151 new, 415 increased, 333 reduced and 164 closed positions. Its largest new stake was Biogen: 175,817 shares worth $41.1M. The largest sale was Allergan plc, an estimated $51.9M.
By sector, the portfolio is most concentrated in Technology at 19% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
- Jacobs Levy Equity Management's largest Q2 2019 buy was Biogen: 175,817 shares worth $41.1M.
- Jacobs Levy Equity Management added most to Ecolab in Q2 2019, an estimated $35.6M increase.
- Jacobs Levy Equity Management's biggest Q2 2019 reduction was EOG Resources, cutting an estimated $33.8M.
- Jacobs Levy Equity Management fully exited Allergan plc in Q2 2019, selling an estimated $51.9M.
- Jacobs Levy Equity Management's ten largest holdings make up 15% of its $7.23B portfolio in Q2 2019.
- Jacobs Levy Equity Management opened 151 new positions and closed 164 in Q2 2019.
- Jacobs Levy Equity Management's portfolio value rose 4.3% quarter-over-quarter to $7.23B.
Based on Jacobs Levy Equity Management's 13F filing for Q2 2019, filed 13 Aug 2019.